Data from I-SPY-2 showed an improved rate of pCR with pembrolizumab concurrent with paclitaxel followed by doxorubicin and cyclophosphamide (T-AC) (pCR 30% vs. 13%) in HR + /HER2-, MammaPrint high-risk breast cancer with tumor size ≥ 2.5 cm [64]. Here, ERBB2 is linked to breast carcinoma.